TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+14.41%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.85B
AUM Growth
+$2.85B
(+6.6%)
Cap. Flow
-$35.8M
Cap. Flow
% of AUM
-1.26%
Top 10 Holdings %
Top 10 Hldgs %
28.19%
Holding
216
New
12
Increased
41
Reduced
45
Closed
16
Top Buys
| 1 |
Thermo Fisher Scientific
TMO
|
$45.7M |
| 2 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$36.7M |
| 3 |
Danaher
DHR
|
$33.8M |
| 4 |
Neurocrine Biosciences
NBIX
|
$22.1M |
| 5 |
DexCom
DXCM
|
$20.7M |
Top Sells
| 1 |
Amgen
AMGN
|
$44.1M |
| 2 |
Merck
MRK
|
$40.6M |
| 3 |
Pfizer
PFE
|
$36.5M |
| 4 |
AbbVie
ABBV
|
$27.3M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
$22.7M |
Sector Composition
| 1 | Healthcare | 95.34% |
| 2 | Real Estate | 2.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Teva Pharmaceuticals
TEVA
$21.1B
| $7.05M | 0.25% | 730,051 -55,800 | -7% | -$538K |
|
102
Charles River Laboratories
CRL
$8.04B
| $7.04M | 0.25% | 28,154 -2,600 | -8% | -$650K |
|
103
TG Therapeutics
TGTX
$4.65B
| $6.93M | 0.24% | +133,269 | New | +$6.93M |
|
104
Xencor
XNCR
$580M
| $6.47M | 0.23% | 148,231 | – | – |
|
105
Arvinas
ARVN
$568M
| $6.24M | 0.22% | +73,459 | New | +$6.24M |
|
106
Agilent Technologies
A
$35.7B
| $6.22M | 0.22% | 52,525 | – | – |
|
107
Teleflex
TFX
$5.59B
| $6.2M | 0.22% | 15,052 -2,200 | -13% | -$905K |
|
108
Denali Therapeutics
DNLI
$2.23B
| $6.06M | 0.21% | +72,333 | New | +$6.06M |
|
|
RVNC
109
DELISTED
Revance Therapeutics, Inc.
RVNC
| $6.06M | 0.21% | 213,808 +127,968 | +149% | +$3.63M |
|
110
Cogent Biosciences
COGT
$1.69B
| $6.04M | 0.21% | 537,742 -565,433 | -51% | -$6.35M |
|
|
BCEL
111
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $5.69M | 0.2% | 352,424 | – | – |
|
|
AMED
112
DELISTED
Amedisys
AMED
| $5.69M | 0.2% | 19,395 | – | – |
|
113
Scholar Rock
SRRK
$3.14B
| $5.63M | 0.2% | +116,094 | New | +$5.63M |
|
114
Align Technology
ALGN
$10.3B
| $5.37M | 0.19% | 10,041 | – | – |
|
115
Revvity
RVTY
$10.5B
| $5.32M | 0.19% | 37,094 -1,400 | -4% | -$201K |
|
|
VRNA
116
Verona Pharma
VRNA
$9.16B
| $5.26M | 0.18% | 751,905 +276,503 | +58% | +$1.94M |
|
|
FMTX
117
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $5.23M | 0.18% | +149,825 | New | +$5.23M |
|
118
Zai Lab
ZLAB
$3.68B
| $5.08M | 0.18% | 37,523 | – | – |
|
119
Centene
CNC
$14.3B
| $5.05M | 0.18% | 84,145 -374,168 | -82% | -$22.5M |
|
|
RETA
120
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $4.73M | 0.17% | 38,219 -38,221 | -50% | -$4.73M |
|
121
Healthpeak Properties
DOC
$12.5B
| $4.55M | 0.16% | 150,392 | – | – |
|
122
Novo Nordisk
NVO
$251B
| $4.53M | 0.16% | 64,906 -69,099 | -52% | -$4.83M |
|
123
uniQure
QURE
$896M
| $4.52M | 0.16% | 125,003 +61,964 | +98% | +$2.24M |
|
124
Addus HomeCare
ADUS
$2.12B
| $4.41M | 0.15% | 37,640 +21,671 | +136% | +$2.54M |
|
125
Smith & Nephew
SNN
$16.3B
| $4.2M | 0.15% | 99,560 | – | – |
|